Inhibition of Transglutaminase 2 as a Therapeutic Strategy in Celiac Disease—In Vitro Studies in Intestinal Cells and Duodenal Biopsies

Enzymatic modification of gliadin peptides by human transglutaminase 2 (TG2) is a key mechanism in the pathogenesis of celiac disease (CD) and represents a potential therapeutic target. Recently, we have identified the small oxidative molecule PX-12 as an effective inhibitor of TG2 in vitro. In this...

Descripción completa

Detalles Bibliográficos
Autores principales: Stricker, Sebastian, de Laffolie, Jan, Zimmer, Klaus-Peter, Rudloff, Silvia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10002517/
https://www.ncbi.nlm.nih.gov/pubmed/36902226
http://dx.doi.org/10.3390/ijms24054795

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10002517/
https://www.ncbi.nlm.nih.gov/pubmed/36902226
http://dx.doi.org/10.3390/ijms24054795

Ejemplares similares